Levomilnacipran in the treatment of major depressive disorder : An analysis of efficacy and safety data from two phase III studies

被引：0
|
作者：
Greenberg, W. [1 ]
Commoll, C. [1 ]
Bose, A. [1 ]
Li, H. [1 ]
Ruth, A. [2 ]
Hussainzada, N. [3 ]
机构：
[1] Forest Res Inst, Jersey City, NJ USA
[2] Prescott Med, Commun Grp, Chicago, IL USA
[3] Forest Labs Inc, Washington, DC USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2012年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-14-014
引用
收藏
页码：184 / 184
页数：1
相关论文
共 50 条
  • [41] Measures of suicidality in phase 3 clinical trials of levomilnacipran ER in adults with major depressive disorder
    Thase, Michael E.
    Gommoll, Carl
    Chen, Changzheng
    Kramer, Kenneth
    Khan, Arif
    Durgam, Suresh
    CNS SPECTRUMS, 2017, 22 (06) : 475 - 483
  • [42] EFFICACY AND SAFETY OF BREXPIPRAZOLE AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER: OVERVIEW OF FOUR SHORT-TERM STUDIES
    Hobart, M.
    Zhang, P.
    Weiss, C.
    Meehan, S.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 144 - 144
  • [43] Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies
    Thase, Michael E.
    Zhang, Peter
    Weiss, Catherine
    Meehan, Stine Rasmussen
    Hobart, Mary
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1907 - 1916
  • [44] Clinical relevance of levomilnacipran ER treatment in major depressive disorder: improvements in functional impairment categories
    Cutler, A.
    Gommoll, C.
    Chen, C.
    Greenberg, W. M.
    Ruth, A.
    D'Souza, I.
    Terner-Rosenthal, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S461 - S461
  • [45] Duloxetine for the treatment of major depressive disorder: A closer look at efficacy and safety data across the approved dose range
    Mallinckrodt, Craig H.
    Prakash, Apurva
    Andorn, Anne C.
    Watkin, John G.
    Wohlreich, Madelaine M.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2006, 40 (04) : 337 - 348
  • [46] LEVOMILNACIPRAN HYDROCHLORIDE Serotonin and Norepinephrine Reuptake Inhibitor Treatment of Major Depressive Disorder Treatment of Ischemic Stroke
    Haddley, K.
    DRUGS OF THE FUTURE, 2012, 37 (12) : 841 - 845
  • [47] Effects of Levomilnacipran ER on Cognition and Functioning in Patients with Major Depressive Disorder: Post Hoc Analysis of a Phase 3 Trial
    Harvey, Philip
    Gommoll, Carl
    Chen, Changzheng
    Lipschutz, Alan
    Wesnes, Keith
    NEUROPSYCHOPHARMACOLOGY, 2014, 39 : S361 - S362
  • [48] Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials
    Shi, Ligen
    Wang, Jingyi
    Xu, Shenbin
    Lu, Yunrong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3899 - 3907
  • [49] Efficacy, tolerability and safety of mirtazapine in the treatment of major depressive disorder due to Parkinson disease
    Iglesias, G
    Weiser, R
    Hernández-Rojas, J
    Flores, J
    Gallardo, M
    García, LM
    Grau, M
    JOURNAL OF AFFECTIVE DISORDERS, 2004, 78 : S119 - S119
  • [50] Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant major depressive disorder
    Shelton, R
    Tollefson, GD
    Tohen, M
    Jacobs, T
    Buras, W
    Spencer, K
    Gannon, KS
    Stahl, S
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 297 - 298
12345